Neurology® Podcast

Dr. Luciano A. Sposato, a specialist in embolic strokes, dives into the complex world of cardiac monitoring and anticoagulation. He discusses the pivotal research on embolic stroke of undetermined source, highlighting the challenges of secondary stroke prevention. The conversation covers evolving treatment protocols for patients with undiagnosed atrial fibrillation, the significance of personalized strategies, and innovative approaches using biomarkers and wearable tech for stroke risk prediction. It's a fascinating look at reshaping stroke management.

Dr. Gaspard Gerschenfeld, a medical expert in thrombolytics, joins the conversation to discuss the implications of tenecteplase and alteplase in treating patients with large ischemic cores. He highlights a comparative study showing tenecteplase leads to better outcomes and lower mortality compared to alteplase at three months. The use of MRI versus CT scans in stroke assessment is also explored, emphasizing the importance of accurate imaging in urgent care. The dialogue stresses the need for further research to enhance stroke treatment efficacy.

Dr. Jason Crowell, an expert on ethical considerations in prodromal Parkinson disease, joins Dr. Colin Hoy, a specialist in diagnosis. They delve into the early signs of the condition, from smell changes to sleep disorders. The conversation covers the ethical dilemmas of diagnosing patients early, discussing the emotional and societal impacts. They also highlight disparities in access to testing for marginalized groups and emphasize the importance of shared decision-making and the evolving role of biomarkers in treatment.

Dr. Géraldine Androdias reveals how immune checkpoint inhibitors affect multiple sclerosis, highlighting a low risk of relapse in MS patients undergoing cancer treatments. Dr. Bob Fox dives into the significance of neurofilament light chain as a biomarker for disease progression, stressing the need for more research. Dr. Ellen Iacobaeus discusses the unique clinical traits of late-onset MS, advocating for personalized therapy approaches. Additionally, insights on family planning for MS patients underscore the importance of supportive discussions between patients and healthcare providers.

Dr. Halley Alexander, a prenatal care expert, joins Dr. Kimford J. Meador, a specialist in antiseizure medications, to discuss the impact of prenatal exposure on child development. They explore a study revealing no major differences in children's creativity but significant declines in executive function with higher medication exposure. The conversation delves into the risks of valproic acid, considerations for alternative medications, and the importance of folic acid supplementation for pregnant women with epilepsy. Their findings underscore the need for careful medication management.

Dr. Matthew Barrett, an expert in Parkinson disease, and Dr. Michael S. Okun, a prominent researcher in biomarkers, delve into the intricacies of biological staging in Parkinson disease. They discuss the ongoing need for caution when redefining classifications, emphasizing the importance of alpha-synuclein biomarkers. The duo highlights challenges in personalized staging and the complexities of diagnosis, while advocating for adaptive systems that can evolve alongside research. Their conversation underlines the necessity for inclusive dialogue and equitable access in advancing care.

Dr. Andy Southerland talks with Dr. Lidia Moura about the implications of large language models (LLMs) for neurologic care. Read the related article in Neurology. Disclosures can be found at Neurology.org.

Dr. Michael R. Wilson and Dr. John Pluvinage discuss their discovery of anti-CD320 antibodies in B12 deficiency patients with neurological symptoms, highlighting potential implications for diagnosis and treatment. They explore the role of antibodies impairing B12 transport into the brain, new insights into autoimmune neurology, and advancements in understanding autoimmune diseases.

Dr. Campbell Le Heron discusses the association of clinical and neurocognitive factors with apathy in Parkinson disease. They explore the complexities of apathy beyond dopamine deficiencies, the importance of early detection, and the impact of apathy on mortality. Counseling strategies and treatment options are also highlighted.

Dr. Andrew McKeon discusses autoimmune neurology, focusing on Paraneoplastic CAMKV autoimmune encephalitis. Topics include limitations of Paraneoplastic Panel screening, the role of CAM-KV antibody in encephalitis, and managing autoimmune disease during cancer treatment.